Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO for cognitive side effects of electroconvulsive therapy
2016-002326-36Phase 3Completed
- Sponsor
- Region Hovedstadens Psykiatri
- Start
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) and bipolar disorder (BD) comparing Eprex add-on to electroconvulsive therapy with Placebo add-on to electroconvulsive therapy (2 arms). Primary endpoint: Change in cognitive composite score. Started Jun 2016; status: completed.
02
Drugs
epoetin alfa
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on 2016-002326-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002326-36.